Adverse Childhood Experiences in Alcohol Use Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05048758|
Recruitment Status : Not yet recruiting
First Posted : September 17, 2021
Last Update Posted : September 17, 2021
|Condition or disease||Intervention/treatment|
|Alcohol Use Disorder Trauma, Psychological||Other: No intervention|
The aim of this study is to examine the impact of ACE on stress sensitivity, cue-reactivity, and emotion processing in individuals with AUD at a longitudinal level. For this, participants (excluding healthy controls) from the first project (see https://clinicaltrials.gov/ct2/show/NCT03758053) will be re-examined after 2 to 2.5 years to explore the involvement of these mechanisms in relation to (long-term) relapse risk, which is a central issue in substance use disorders. Furthermore, we will investigate cognitive functions, specifically response inhibition and working memory, in the relationship between ACE and AUD. Additional participants may be recruited to mitigate sample attrition from the first project and to achieve the desired sample size. To assess cognitive functions and data from new participants in relation to relapse risk, we will perform a 3-month follow-up. (Neuro-)biological and physiological mechanisms underlying AUD after ACE will be studied.
Neural correlates of stress-sensitivity, emotion processing, alcohol cue-reactivity and cognitive functions will be assessed using fMRI. Furthermore, blood and saliva samples will be used to assess biological and physiological mechanisms (e.g. salivary cortisol level or genetic markers of AUD and possible gene-environment-interactions).
The current project is interested in the extent to which ACE severity modulates neural activation in specific brain regions during the execution of fMRI paradigms as well as alcohol-related measures (e.g., craving and alcohol consumption). Of particular interest is the question whether these neural and alcohol-related measures are associated with relapse risk.
60 individuals (60 individuals with AUD and varying levels of ACE) will be examined using interviews, questionnaires and fMRI tasks as well as saliva and blood samples. Depending on ACE severity, participants will be divided into two groups, namely one group with no or mild ACE and another group with moderate to severe ACE. All ethical votes and informed consents of participants are and will be obtained according to the declaration of Helsinki.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Vulnerability for Alcohol Use Disorder After ACE: the Role of Stress Sensitivity, Emotion Processing, Cue Reactivity and Cognitive Functions in Relapse Risk|
|Estimated Study Start Date :||September 2021|
|Estimated Primary Completion Date :||December 2023|
|Estimated Study Completion Date :||December 2023|
Individuals with AUD + moderate to severe ACE
Individuals with alcohol use disorder (AUD) and moderate to severe adverse childhood experiences (ACE)
Other: No intervention
Other Name: Observational study
Individuals with AUD + no or mild ACE
Individuals with alcohol use disorder (AUD) and no or mild adverse childhood experiences (ACE)
Other: No intervention
Other Name: Observational study
- fMRI to assess group and within-subjects differences in task-specific brain activation patterns: Stress-sensitivity [ Time Frame: fMRI measurement at one day only (day of fMRI experiment) ]Stress-sensitivity: Imaging Stress Task to assess neural activation patterns during mental arithmetic tasks with negative feedback
- fMRI to assess group and within-subjects differences in task-specific brain activation patterns: Emotion processing [ Time Frame: fMRI measurement at one day only (day of fMRI experiment) ]Emotion-processing: emotional face-/form-matching task to assess neural activation patters of emotion processing
- fMRI to assess group and within-subjects differences in task-specific brain activation patterns: Alcohol cue-reactivity [ Time Frame: fMRI measurement at one day only (day of fMRI experiment) ]Alcohol cue-reactivity: pictures of alcoholic beverages to assess neural alcohol-cue reactivity
- fMRI to assess group differences in task-specific brain activation patterns: Response inhibition [ Time Frame: fMRI measurement at one day only (day of fMRI experiment) ]Response inhibition: Stop Signal Task (variation of go/no-go) to assess response inhibition.
- fMRI to assess group differences in task-specific brain activation patterns: Working memory [ Time Frame: fMRI measurement at one day only (day of fMRI experiment) ]Working memory: n-back task (continuous performance) to assess working memory function.
- Long-term alcohol consumption [ Time Frame: 2 - 2.5 year follow-up after first project ]Self-report in longitudinal sample measured with the LDH interview
- Short-term alcohol consumption [ Time Frame: 3-month follow-up after current project ]Self-report in whole sample measured with the Form 90 interview
- Hormonal stress response using salivary cortisol level [ Time Frame: Normal awakening response on a subject's regular week-day (0, 0.5, 8 and 14 hours after wake-up) ]
Collection of saliva on a subject's regular week-day for the individual's normal cortisol awakening response and circadian rhythm (basal hypothalamic-pituitary-adrenal-function at 0, 0.5, 8 and 14 hours after wake-up).
Cortisol awakening reaction, area under the curve and slope will therefore be calculated [nmol/L]
- Hormonal stress response using salivary cortisol level [ Time Frame: day of fMRI experiment, at -45, -22, -10 minutes before and 35, 45, 60, 75 and 90 minutes after onset of stress induction ]Time course of salivary cortisol level. Area under the curve and slope will be calculated [nmol/L]
- GWAS and especially glutamatergic, serotonergic single-nucleotide polymorphisms [ Time Frame: Blood sample at one day only (day of fMRI experiment) ]Genomic DNA using 40ml EDTA-blood
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05048758
|Contact: Sabine Vollstaedt-Klein||0621 / 1703 - 3912||Sabine.Vollstaedt-Klein@zi-mannheim.de|
|Klinik für Abhängiges Verhalten, Zentralinstitut für Seelische Gesundheit|
|Mannheim, Baden-Württemberg, Germany, 68159|